Mark | Date Date | Title Title | |||
---|---|---|---|---|---|
No. 1 | 14 Feb 2018 |
Users' Handbook supplement to the Guidance Document for developing and assessing Adverse Outcome Pathways
This document is a supplement to the Guidance Document for developing and assessing Adverse Outcome Pathways (AOPs). It provides focused and practical instructions for both AOP developers and reviewers and is intended to assist in identifying,... |
|||
No. 28 | 15 Dec 2022 |
Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation
This Adverse Outcome Pathway (AOP) describes the linkage between uncoupling of oxidative phosphorylation (OXPHOS) and growth inhibition via decreased cell proliferation. The mitochondrial OXPHOS machinery is a key physiological process responsible... |
|||
No. 26 | 15 Dec 2022 |
Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation
This Adverse Outcome Pathway (AOP) describes the linkage between Thyroperoxidase inhibition and increased mortality via reduced anterior swim bladder inflation. The swim bladder is a gas-filled organ found in many bony fish species and typically... |
|||
No. 33 | 12 Dec 2023 |
Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis
Lung fibrosis is a dysregulated or exaggerated tissue repair process resulting in the thickening or scarring of lung tissue. It involves the presence of sustained or repeated exposure to a stressor and intricate dynamics between several inflammatory... |
|||
No. 29 | 11 Jul 2023 |
Oxidative DNA damage leading to chromosomal aberrations and mutations
This Adverse Outcome Pathway (AOP) describes the linkage between oxidative DNA damage and irreversible genomic damage (chromosomal aberrations and mutations). DNA damage is considered an important contributor to the adverse health effects of many... |
|||
No. 21 | 15 Dec 2022 |
Inhibitor binding to topoisomerase II leading to infant leukaemia
This Adverse Outcome Pathway (AOP) describes the linkages between the perturbation of the normal topoisomerase II enzyme function and infant leukaemia. Infant leukaemia is a rare haematological disease (1 in 106 newborns, accounting for 10% of all... |
|||
No. 31 | 23 Oct 2023 |
Disruption of VEGFR signaling leading to developmental defects
The cardiovascular system is the first functional organ system to develop in the vertebrate embryo, reflecting its critical role during normal development and pregnancy. This Adverse Outcome Pathway focuses on the regulation and disruption of... |
|||
No. 22 | 15 Dec 2022 |
Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation
This Adverse Outcome Pathway (AOP) describes the linkage between Deiodinase 2 inhibition and increased mortality via reduced posterior swim bladder inflation. The swim bladder is a gas-filled organ found in many bony fish species and typically... |
|||
No. 23 | 15 Dec 2022 |
Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation
This Adverse Outcome Pathway (AOP) describes the linkage between Deiodinase 2 inhibition and increased mortality via reduced anterior swim bladder inflation. The swim bladder is a gas-filled organ found in many bony fish species and typically... |
|||
No. 24 | 15 Dec 2022 |
Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation
This Adverse Outcome Pathway (AOP) describes the linkage between Deiodinase 1 inhibition and increased mortality via reduced posterior swim bladder inflation. The swim bladder is a gas-filled organ found in many bony fish species and typically... |
|||
No. 25 | 15 Dec 2022 |
Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation
This Adverse Outcome Pathway (AOP) describes the linkage between Deiodinase 1 inhibition and increased mortality via reduced anterior swim bladder inflation. The swim bladder is a gas-filled organ found in many bony fish species and typically... |
|||
No. 27 | 15 Dec 2022 |
Chitin synthase 1 inhibition leading to mortality
This Adverse Outcome Pathway (AOP) describes the linkage between Chitin synthase 1 inhibition and mortality in arthropods. In order to grow and develop, arthropods need to shed their exoskeleton (or cuticle) periodically and replace it with a new one... |
|||
No. 20 | 15 Dec 2022 |
Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leading to impairment of learning and memory
This Adverse Outcome Pathway (AOP) describes the linkage between binding to proteins involved in protection against oxidative stress and impairment in learning and memory. Production, binding and degradation of Reactive Oxygen Radicals are tightly... |
|||
No. 18 | 15 Oct 2021 |
Adverse Outcome Pathway on inhibition of calcineurin activity leading to impaired T-cell dependent antibody response
The present AOP describes the inhibition of calcineurin activity resulting in impaired T-Cell Dependent Antibody Response (TDAR). Calcineurin (CN), a protein phosphatase, is known to impair immune function when its phosphatase activation is... |
|||
No. 13 | 30 Jul 2019 |
Adverse Outcome Pathway on inhibition of Thyroperoxidase and subsequent adverse neurodevelopmental outcomes in mammals
This AOP describes one adverse outcome that may result from the inhibition of thyroperoxidase (TPO) during mammalian development. Chemical inhibition of TPO results in decreased thyroid hormone (TH) synthesis, and subsequent reduction in circulating... |
|||
No. 14 | 30 Jul 2019 |
Adverse Outcome Pathway on inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment
The thyroid hormones (TH) are essential for brain development, maturation, and function as they regulate the early key developmental processes. Normal human brain development and cognitive function relays on sufficient production of TH during the... |
|||
No. 30 | 23 Oct 2023 |
Adverse Outcome Pathway on impaired interleukin-1 receptor type I (IL-1R1) signaling leading to impaired T-cell dependent antibody response
Stressors that exhibit immunosuppression might act by different mechanisms, i.e. alter the number of cells involved in the immune response, the ability of the cells to produce cytokines, chemokines, antibodies or growth factors, the composition of... |
|||
No. 17 | 15 Oct 2021 |
Adverse Outcome Pathway on histone deacetylase inhibition leading to testicular atrophy
The present AOP describes inhibition of histone deacetylase resulting in testicular atrophy. Histone deacetylase inhibitors (HDIs) are approved as anti-cancer drugs since HDIs have apoptotic effects in cancer cells. The intracellular mechanisms of... |
|||
No. 32 | 23 Oct 2023 |
Adverse Outcome Pathway on deposition of energy leading to lung cancer
The present Adverse Outcome Pathway (AOP) describes the linkage between lung cancer initiated from the Deposition of Energy (DoE) into a cell by a prototypic stressor such as radon gas. The multiple ionization events from DoE can directly break DNA... |
|||
No. 8 | 12 Oct 2018 |
Adverse Outcome Pathway on chronic binding of antagonist to N-methyl-D-aspartate receptors during brain development leading to neurodegeneration with impairment in learning and memory in aging
This AOP links chronic NMDA receptors inhibition during brain development to neurodegeneration in hippocampus and cortex with amyloid plaque deposition and tau hyperphosphorylation, and impairment of learning and memory, which are considered as... |
OECD Series on Adverse Outcome Pathways
An Adverse Outcome Pathway (AOP) describes a logical sequence of causally linked events at different levels of biological organisation, which follows exposure to a stressor and leads to an adverse health effect in humans or wildlife. AOPs are the central element of a toxicological knowledge framework, promoted by member countries through OECD, built to support chemical risk assessment based on mechanistic reasoning. These AOPs are available in the AOP-Wiki, an interactive and virtual encyclopaedia for AOP development. Following their development and review, the endorsed AOPs are published in the OECD Series on Adverse Outcome Pathways. As scientific knowledge progresses, the publication of an AOP in this series does not preclude regular updates or new contributions to a given AOP. While the AOP-Wiki is a dynamic tool, only impactful changes to the AOP will be reflected in subsequent updates of the published AOP.
English
- ISSN: 2415170X (online)
- https://doi.org/10.1787/2415170X
1 - 20 of 35 results
Users' Handbook supplement to the Guidance Document for developing and assessing Adverse Outcome Pathways
OECD
14 Feb 2018
This document is a supplement to the Guidance Document for developing and assessing Adverse Outcome Pathways (AOPs). It provides focused and practical instructions for both AOP developers and reviewers and is intended to assist in identifying,...
Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation
You Song and Daniel L. Villeneuve
15 Dec 2022
This Adverse Outcome Pathway (AOP) describes the linkage between uncoupling of oxidative phosphorylation (OXPHOS) and growth inhibition via decreased cell proliferation. The mitochondrial OXPHOS machinery is a key physiological process responsible...
Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation
Lucia Vergauwen, Evelyn Stinckens, Daniel L. Villeneuve and Dries Knapen
15 Dec 2022
This Adverse Outcome Pathway (AOP) describes the linkage between Thyroperoxidase inhibition and increased mortality via reduced anterior swim bladder inflation. The swim bladder is a gas-filled organ found in many bony fish species and typically...
Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis
Sabina Halappanavar, Monita Sharma, Silvia Solorio-Rodriguez, Hakan Wallin, Ulla Vogel, Kristie Sullivan and Amy J. Clippinger
12 Dec 2023
Lung fibrosis is a dysregulated or exaggerated tissue repair process resulting in the thickening or scarring of lung tissue. It involves the presence of sustained or repeated exposure to a stressor and intricate dynamics between several inflammatory...
Oxidative DNA damage leading to chromosomal aberrations and mutations
Eunnara Cho, Ashley Allemang, Marc Audebert, Vinita Chauhan, Stephen Dertinger, Giel Hendriks, Mirjam Luijten, Francesco Marchetti, Sheroy Minocherhomji, Stefan Pfuhler, Daniel J. Roberts, Kristina Trenz and Carole L. Yauk
11 Jul 2023
This Adverse Outcome Pathway (AOP) describes the linkage between oxidative DNA damage and irreversible genomic damage (chromosomal aberrations and mutations). DNA damage is considered an important contributor to the adverse health effects of many...
Inhibitor binding to topoisomerase II leading to infant leukaemia
Olavi Pelkonen, Andrea Terron, Antonio F. Hernandez, Pablo Menendez and Susanne Hougaard Bennekou
15 Dec 2022
This Adverse Outcome Pathway (AOP) describes the linkages between the perturbation of the normal topoisomerase II enzyme function and infant leukaemia. Infant leukaemia is a rare haematological disease (1 in 106 newborns, accounting for 10% of all...
Disruption of VEGFR signaling leading to developmental defects
Thomas B. Knudsen, Katerine Saili, Jill Franzosa, Nancy Baker, Richard Spencer, Tamara Tal, Nicole Kleinstreuer, Tuula Heinonen, Rob Ellis-Hutchings, Neil Vargesson and Maria Bondesson
23 Oct 2023
The cardiovascular system is the first functional organ system to develop in the vertebrate embryo, reflecting its critical role during normal development and pregnancy. This Adverse Outcome Pathway focuses on the regulation and disruption of...
Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation
Lucia Vergauwen, Evelyn Stinckens, Daniel L. Villeneuve and Dries Knapen
15 Dec 2022
This Adverse Outcome Pathway (AOP) describes the linkage between Deiodinase 2 inhibition and increased mortality via reduced posterior swim bladder inflation. The swim bladder is a gas-filled organ found in many bony fish species and typically...
Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation
Lucia Vergauwen, Evelyn Stinckens, Daniel L. Villeneuve and Dries Knapen
15 Dec 2022
This Adverse Outcome Pathway (AOP) describes the linkage between Deiodinase 2 inhibition and increased mortality via reduced anterior swim bladder inflation. The swim bladder is a gas-filled organ found in many bony fish species and typically...
Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation
Lucia Vergauwen, Evelyn Stinckens, Daniel L. Villeneuve and Dries Knapen
15 Dec 2022
This Adverse Outcome Pathway (AOP) describes the linkage between Deiodinase 1 inhibition and increased mortality via reduced posterior swim bladder inflation. The swim bladder is a gas-filled organ found in many bony fish species and typically...
Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation
Lucia Vergauwen, Evelyn Stinckens, Daniel L. Villeneuve and Dries Knapen
15 Dec 2022
This Adverse Outcome Pathway (AOP) describes the linkage between Deiodinase 1 inhibition and increased mortality via reduced anterior swim bladder inflation. The swim bladder is a gas-filled organ found in many bony fish species and typically...
Chitin synthase 1 inhibition leading to mortality
Simon Schmid, You Song and Knut Erik Tollefsen
15 Dec 2022
This Adverse Outcome Pathway (AOP) describes the linkage between Chitin synthase 1 inhibition and mortality in arthropods. In order to grow and develop, arthropods need to shed their exoskeleton (or cuticle) periodically and replace it with a new one...
Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leading to impairment of learning and memory
Florianne Tschudi-Monnet, Marie-Gabrielle Zurich, Carolina Nunes, Jenny Sandström, Rex FitzGerald, Michael Aschner and Joao Rocha
15 Dec 2022
This Adverse Outcome Pathway (AOP) describes the linkage between binding to proteins involved in protection against oxidative stress and impairment in learning and memory. Production, binding and degradation of Reactive Oxygen Radicals are tightly...
Adverse Outcome Pathway on inhibition of calcineurin activity leading to impaired T-cell dependent antibody response
Hiroyuki Komatsu, Junichiro Sugimoto, Ken Goto, Kiyoshi Kushima, Naohisa Tsutsui, Shigeru Hisada, Shiho Ito, Tadashi Kosaka, Takumi Ohishi, Yasuharu Otsubo and Yoshihiro Takahashi
15 Oct 2021
The present AOP describes the inhibition of calcineurin activity resulting in impaired T-Cell Dependent Antibody Response (TDAR). Calcineurin (CN), a protein phosphatase, is known to impair immune function when its phosphatase activation is...
Adverse Outcome Pathway on inhibition of Thyroperoxidase and subsequent adverse neurodevelopmental outcomes in mammals
Kevin M. Crofton, Mary Gilbert, Katie Paul Friedman, Barbara Demeneix, Mary Sue Marty and R. Thomas Zoeller
30 Jul 2019
This AOP describes one adverse outcome that may result from the inhibition of thyroperoxidase (TPO) during mammalian development. Chemical inhibition of TPO results in decreased thyroid hormone (TH) synthesis, and subsequent reduction in circulating...
Adverse Outcome Pathway on inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment
Alexandra Rolaki, Francesca Pistollato, Sharon Munn and Anna Bal-Price
30 Jul 2019
The thyroid hormones (TH) are essential for brain development, maturation, and function as they regulate the early key developmental processes. Normal human brain development and cognitive function relays on sufficient production of TH during the...
Adverse Outcome Pathway on impaired interleukin-1 receptor type I (IL-1R1) signaling leading to impaired T-cell dependent antibody response
Yutaka Kimura, Setsuya Aiba, Takao Ashikaga, Takumi Ohishi and Kiyoshi Kushima
23 Oct 2023
Stressors that exhibit immunosuppression might act by different mechanisms, i.e. alter the number of cells involved in the immune response, the ability of the cells to produce cytokines, chemokines, antibodies or growth factors, the composition of...
Adverse Outcome Pathway on histone deacetylase inhibition leading to testicular atrophy
Shihori Tanabe, Akihiko Hirose and Takashi Yamada
15 Oct 2021
The present AOP describes inhibition of histone deacetylase resulting in testicular atrophy. Histone deacetylase inhibitors (HDIs) are approved as anti-cancer drugs since HDIs have apoptotic effects in cancer cells. The intracellular mechanisms of...
Adverse Outcome Pathway on deposition of energy leading to lung cancer
Samantha Sherman, Zakara Said, Baki Sadi, Carole Yauk, Danielle Beaton, Ruth Wilkins, Robert Stainforth, Nadine Adam and Vinita Chauhan
23 Oct 2023
The present Adverse Outcome Pathway (AOP) describes the linkage between lung cancer initiated from the Deposition of Energy (DoE) into a cell by a prototypic stressor such as radon gas. The multiple ionization events from DoE can directly break DNA...
Adverse Outcome Pathway on chronic binding of antagonist to N-methyl-D-aspartate receptors during brain development leading to neurodegeneration with impairment in learning and memory in aging
Florianne Tschudi-Monnet and Rex FitzGerald
12 Oct 2018
This AOP links chronic NMDA receptors inhibition during brain development to neurodegeneration in hippocampus and cortex with amyloid plaque deposition and tau hyperphosphorylation, and impairment of learning and memory, which are considered as...